Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CES2 | O00748 | 1/20 | 1.00 |
| ▸ | CES1 | P23141 | 1/20 | 1.00 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.70 |
| ▸ | LMNA | P02545 | 3/20 | 0.70 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.70 |
| ▸ | P4HTM | Q9NXG6 | 1/20 | 0.70 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.61 |
| ▸ | GSK3B | P49841 | 1/20 | 0.59 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | NPC1 | O15118 | 2/20 | 0.52 |
| ▸ | RAB9A | P51151 | 2/20 | 0.52 |
| ▸ | MAPT | P10636 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.50 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.50 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.50 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.50 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.50 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29466797 | 1.00 | CES2 (1.00) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL29466796 | 1.00 | CES2 (1.00) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL29976899 | 0.90 | CES2 (0.82) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL30161092 | 0.89 | CES1 (0.79) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL5012058 | 0.89 | CES1 (0.79) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL15180861 | 0.88 | CES2 (0.78) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL15180866 | 0.88 | CES2 (0.78) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL15180869 | 0.88 | CES2 (0.78) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL15180873 | 0.88 | CES2 (0.78) | CES2CES1L3MBTL1LMNANAPRT | |
| SCHEMBL15180867 | 0.88 | CES2 (0.78) | CES2CES1L3MBTL1LMNANAPRT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 297 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12162877-B2 | Human dihydroorotate dehydrogenase (hDHODH) inhibitors and their use in targeting oncological diseases sensitive to pyrimidine starvation | DRUG DISCOVERY AND CLINIC S.R.L. (IT) | 2024-12-10 | — | — | US | claimed |
| EP-3820929-B1 | COORDINATION POLYMER OF A PRECURSOR CONTAINING CU(I) IONS | CENTRE NAT RECH SCIENT (FR) | 2024-12-04 | — | — | EP | claimed |
| US-20240308996-A1 | PYRIDOPYRIDINES AND DERIVATIVES THEREOF AS SELECTIVE KINASE INHIBITORS | UNIVERSITY OF SHARJAH (AE) | 2024-09-19 | — | — | US | claimed |
| EP-4013756-B1 | MLL1 INHIBITORS AND ANTI-CANCER AGENTS | NOVARTIS AG (CH) | 2024-05-08 | — | — | EP | claimed |
| EP-2025697-B1 | Process to obtain dimers, trimers and up to polymers from pyridinemethanol derivatives compounds | BENEMERITA UNIVERSIDAD AUTONOMA DE PUEBLA (MX) | 2013-12-18 | — | — | EP | claimed |
| US-7989583-B2 | Process to obtain dimers, trimers and up to polymers from pyridinmethanol derivatives compounds | BENEMERITA UNIVERSIDAD AUTONOMA DE PUEBLA (MX) | 2011-08-02 | — | — | US | claimed |
| US-7973034-B2 | Ameliorating toxic effects of such as cancer therapy drugs or addictive drug overdose | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2011-07-05 | — | — | US | claimed |
| EP-2025697-A1 | Process to obtain dimers, trimers and up to polymers from pyridinemethanol derivatives compounds | Benemerita Universidad Autonoma de Puebla (MX) | 2009-02-18 | — | — | EP | claimed |
| US-20090043063-A1 | Process to obtain dimers, trimers and up to polymers from pyridinmethanol derivatives compounds | PERCINO ZACARIAS, Maria Judith (MX) | 2009-02-12 | — | — | US | claimed |
| US-20070191368-A1 | Inhibition of tissue damage to skin from radiation treatment therapy | BISSETT DONALD L | 2007-08-16 | — | — | US | claimed |
| WO-2003002119-A1 | TREATMENT AND PREVENTION OF LIPODERMATOSCLEROSIS | JOHNSON & JOHNSON MEDICAL LIMITED (GB) | 2003-01-09 | — | — | WO | claimed |
| US-5780459-A | SALICYLIC ACID WITH ADDITIONAL ACTIVE MATERIALS | THE PROCTER & GAMBLE COMPANY (US) | 1998-07-14 | — | — | US | claimed |
| US-5487884-A | CYTOPROTECTIVE AGENTS BY RADIATION RESISTANCE TO PREVENT SKIN CANCER AND PREMATURE AGING | THE PROCTER & GAMBLE COMPANY (US) | 1996-01-30 | — | — | US | claimed |
| EP-0313305-A2 | Photoprotection compositions comprising chelating agents | THE PROCTER & GAMBLE COMPANY (US) | 1989-04-26 | — | — | EP | claimed |
| EP-0090443-B1 | A PROCESS FOR CARBONYLATING METHANOL TO ACETIC ACID AND/OR METHYL ACETATE | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1988-06-22 | — | — | EP | claimed |
| EP-0090443-A2 | A process for carbonylating methanol to acetic acid and/or methyl acetate | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1983-10-05 | — | — | EP | claimed |
| US-4001131-A | BLEACHING | THE PROCTER & GAMBLE COMPANY (US) | 1977-01-04 | — | — | US | claimed |
| US-12629359-B2 | Structural analogues of methylphenidate as Parkinson's disease-modifying agents | UNIVERSITA' DEGLI STUDI DI BRESCIA (IT) | 2026-05-19 | — | — | US | disclosed |
| EP-0086281-A1 | Preparation of carbamates using a palladium-containing catalyst | SHELL INTERNATIONALE RESEARCHMAATSCHAPPIJ B.V. (NL) | 1983-08-24 | — | — | EP | disclosed |
| US-4001131-A | BLEACHING | THE PROCTER & GAMBLE COMPANY (US) | 1977-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12162877-B2 | Human dihydroorotate dehydrogenase (hDHODH) inhibitors and their use in targeting oncological diseases sensitive to pyrimidine starvation | DHODH, DLD, DPYD | CES2 4307/4885CES1 2635/4885L3MBTL1 1927/4885 |
| US-12629359-B2 | Structural analogues of methylphenidate as Parkinson's disease-modifying agents | SNCA, SYNJ1, PARK7 | CES2 3441/4885CES1 3375/4885L3MBTL1 3411/4885 |
| US-20240308996-A1 | PYRIDOPYRIDINES AND DERIVATIVES THEREOF AS SELECTIVE KINASE INHIBITORS | MAP4K2, MAP4K1, MAP3K1 | CES2 3560/4885CES1 2656/4885L3MBTL1 3723/4885 |
| US-20090043063-A1 | Process to obtain dimers, trimers and up to polymers from pyridinmethanol derivatives compounds | PNPO, ADH1A, CYP2E1 | CES2 685/4885CES1 790/4885L3MBTL1 4610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.